Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor ImmunityTrifunctional antibodies that engage natural killer cells by binding NKp46 and CD16, in addition to an antigen on cancer cells, show higher potency than current clinically available therapeutic antibodies.Trifunctional antibodies that engage natural killer cells by binding NKp46 and CD16, in addition to an antigen on cancer cells, show higher potency than current clinically available therapeutic antibodies.Laurent Gauthier, Ariane Morel, Nadia Anceriz, Benjamin Rossi, Audrey Blanchard-Alvarez, Gwendoline Grondin, Sylvia Trichard, Cédric Cesari, Melody Sapet, Frédéric Bosco, Hélène Rispaud-Blanc, Franceline Guillot, Stéphanie Cornen, Alain Roussel, Béatrice Amigues, Guillaume Habif, Flavien Caraguel, Sandrine Arrufat, Romain Remark, François Romagné, Yannis Morel, Emilie Narni-Mancinelli, Eric Vivierhttps://secure.jbs.elsevierhealth.com/action/getSharedSiteSession?redirect=https%3A%2F%2Fwww.cell.com%2Fcell%2Ffulltext%2FS0092-8674%2819%2930460-X%3Frss%3Dyes&rc=0http://www.cell.com/cell/inpress.rssCellCell RSS feed.Wireless News CampaignMay 31, 2019

Powered by WPeMatico